浙江美迪深生物医药

Zhejiang Medisun Biopharmaceutical is a clinical-stage biotechnology company focused on the development of mRNA-based vaccines and therapeutics. Based in Hangzhou, China, the company utilizes a proprietary mRNA synthesis and lipid nanoparticle (LNP) delivery platform to target infectious diseases and oncology. Its lead candidate, MDS-V01, is an mRNA vaccine targeting COVID-19 that has entered clinical evaluation. Beyond COVID-19, Medisun is advancing a pipeline that includes vaccines for respiratory syncytial virus (RSV) and personalized cancer vaccines. The company integrates end-to-end capabilities from sequence design to GMP-compliant manufacturing. Medisun aims to leverage the versatility of mRNA technology to provide innovative solutions for global health challenges.